Belfast Health and Social Care Trust
caring supporting improving together

FOI/37584

27 July 2026

MS Treatments

Q1. How many patients received treatment for any condition in the last six months with any of the following treatment regimens (November 2025 – April 2026)?

- **Ocrevus (ocrelizumab) IV (300mg/30ml)**
- **Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)**
- **Kesimpta (ofatumumab)**
- **Briumvi (ublituximab)**
- **Mavenclad (cladribine)**
- **Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)**
- **Natalizumab (Tysabri and Tyruko)**

Treatment	Nov 2025 -April 2026
Ocrevus (ocrelizumab) IV (300mg/30ml)	176
Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	57
Kesimpta (ofatumumab)	239
Briumvi (ublituximab)	0
Mavenclad (cladribine)	<5
Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	670
Natalizumab (Tysabri and Tyruko)	88

Q1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in May 2025 to October 2025 AND November 2025-April 2026)

- **Ocrevus (ocrelizumab) IV (300mg/30ml)**
- **Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)**
- **Kesimpta (ofatumumab)**
- **Briumvi (ublituximab)**
- **Mavenclad (cladribine)**
- **Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)**
- **Natalizumab (Tysabri and Tyruko)**

Clarification: Q1 is for all patients and Q1a is specific for MS patients

27 July 2026

Question 1a.

Treatment	May 2025 - Oct 2025	Nov 2025 -April 2026
Ocrevus (ocrelizumab) IV (300mg/30ml)	167	176
Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)	54	57
Kesimpta (ofatumumab	38	47
Briumvi (ublituximab)	0	0
Mavenclad (cladribine)	<5	<5
Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)	244	248
Natalizumab (Tysabri and Tyruko)	82	88

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

These figures are for patients who attend BHSCT for treatment only and the data was obtained from the treatment/MRI and Ocrelizumab databases.

Just highlighting that under the Natalizumab section, the figures refer to Tysabri. To date, we have not used the biosimilar Tyruko in BHSCT for MS patients.

We do have patients approved by the DMT panel for treatment with Briumvi (ublituximab); however, to date, no patients at BHSCT have chosen this treatment.

The care pathway has now been completed and we are able to treat patients with Briumvi if they choose it.